INTEGRATED LABORATORY ABNORMALITY PROFILES OF UPADACITINIB WITH UP TO 4.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED IN THE SELECT PHASE 3 PROGRAM

被引：0

作者：

Charles-Schoeman, C. ^{[1
]}

Giles, J. T. ^{[2
]}

Lane, N. ^{[3
]}

Choy, E. ^{[4
]}

Furst, D. ^{[5
]}

Vencovsky, J. ^{[6
]}

Wilson, A. G. ^{[7
]}

Burmester, G. R. ^{[8
]}

Shaw, T. ^{[9
]}

Song, Y. ^{[9
]}

Camp, H. ^{[9
]}

Khan, N. ^{[9
]}

Yee, J. ^{[9
]}

Anyanwu, S. ^{[9
]}

Mcinnes, I. ^{[10
]}

机构：

[1] Univ Calif Los Angeles, Rheumatol, Los Angeles, CA USA

[2] Columbia Univ, Rheumatol, New York, NY USA

[3] Univ Calif Davis, Rheumatol, Sacramento, CA USA

[4] Cardiff Univ, CREATE Ctr, Rheumatol, Cardiff, Wales

[5] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[6] Inst Rheumatol, Rheumatol, Prague, Czech Republic

[7] Univ Coll Dublin, Conway Inst, Ctr Arthrit Res, Dublin, Ireland

[8] Charite, Rheumatol, Berlin, Germany

[9] AbbVie Inc, Immunol, N Chicago, IL USA

[10] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷

关键词：

D O I：

10.1136/annrheumdis-2021-eular.1815

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OP0128

引用

页码：72 / 73

页数：2

共 50 条

[21] Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials
Conaghan, Philip G.
Pavelka, Karel
Hsieh, Song-Chou
Bonnington, Terri-Leigh
Kent, Toby C.
Marchbank, Katie
Edwards, Christopher J.
RHEUMATOLOGY ADVANCES IN PRACTICE, 2022, 7 (01)
[22] Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
Gerd R. Burmester
Kevin Winthrop
Ricardo Blanco
Peter Nash
Philippe Goupille
Valderilio F. Azevedo
Carlo Salvarani
Andrea Rubbert-Roth
Elizabeth Lesser
Ralph Lippe
Apinya Lertratanakul
Reva M. Mccaskill
John Liu
Eric M. Ruderman
Rheumatology and Therapy, 2022, 9 : 521 - 539
[23] Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
Burmester, Gerd R.
Winthrop, Kevin
Blanco, Ricardo
Nash, Peter
Goupille, Philippe
Azevedo, Valderilio F.
Salvarani, Carlo
Rubbert-Roth, Andrea
Lesser, Elizabeth
Lippe, Ralph
Lertratanakul, Apinya
Mccaskill, Reva M.
Liu, John
Ruderman, Eric M.
RHEUMATOLOGY AND THERAPY, 2022, 9 (02) : 521 - 539
[24] Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program
Peterfy, Charles G.
Strand, Vibeke
Friedman, Alan
Hall, Stephen
Mysler, Eduardo
Durez, Patrick
Baraliakos, Xenofon
Enejosa, Jeffrey, V
Shaw, Tim
Li, Yihan
Chen, Su
Song, In-Ho
RHEUMATOLOGY, 2022, 61 (08) : 3246 - 3256
[25] SAFETY PROFILE OF SUBCUTANEOUS ABATACEPT FOCUSING ON CLINICALLY RELEVANT EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND UP TO 4.5 YEARS OF EXPOSURE
Alten, Rieke
Kaine, Jeffrey L.
Keystone, Edward
Nash, Peter T.
Delaet, Ingrid
Qi, Keqin
Genovese, Mark C.
RHEUMATOLOGY, 2012, 51 : 127 - 128
[26] SUSTAINABILITY OF RESPONSE BETWEEN UPADACITINIB AND ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS THROUGH 3 YEARS FROM THE SELECT-COMPARE TRIAL
Nash, P.
Kavanaugh, A.
Buch, M. H.
Combe, B.
Bessette, L.
Song, I. H.
Shaw, T.
Song, Y.
Suboticki, J.
Fleischmann, R. M.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 591 - 592
[27] Sustainability of Response Between Upadacitinib and Adalimumab in Patients With Rheumatoid Arthritis: Results Through 3 Years from the SELECT-COMPARE Trial
Nash, Peter
Kavanaugh, Arthur
Buch, Maya
Combe, Bernard
Bessette, Louis
Song, In-Ho
Shaw, Tim
Song, Yanna
Suboticki, Jessica
Fleischmann, Roy
JOURNAL OF RHEUMATOLOGY, 2022, 49 (07) : 775 - 776
[28] Sustainability of Response Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Results Through 3 Years from the SELECT-COMPARE Trial
Nash, Peter
Kavanaugh, Arthur
Buch, Maya
Combe, Bernard
Bessette, Louis
Song, In-Ho
Shaw, Tim
Song, Yanna
Suboticki, Jessica
Fleischmann, Roy
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1730 - 1733
[29] SUSTAINABILITY OF RESPONSE BETWEEN UPADACITINIB AND ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS THROUGH 3 YEARS FROM THE SELECT-COMPARE TRIAL
Nash, Peter
Kavanaugh, Arthur
Buch, Maya H.
Combe, Bernard
Bessette, Louis
Song, In-Ho
Shaw, Tim
Song, Yanna
Suboticki, Jessica
Fleischmann, Roy
INTERNAL MEDICINE JOURNAL, 2022, 52 : 27 - 27
[30] SUSTAINABILITY OF RESPONSE BETWEEN UPADACITINIB AND ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS THROUGH 3 YEARS FROM THE SELECT-COMPARE TRIAL
Buch, Maya H.
Nash, Peter
Kavanaugh, Arthur
Combe, Bernard
Bessette, Louis
Song, In-Ho
Shaw, Tim
Song, Yanna
Suboticki, Jessica L.
Fleischmann, Roy
RHEUMATOLOGY, 2022, 61

← 1 2 3 4 5 →